On 27 September 2007 Sofia-based Sopharma AD (

) and the Polish Natur Product Zdrovit signed a contract for the establishment of a company, BSE reports.

Sopharma will control 50.01% of the new enterprise. The Polish company operate in the field of production and marketing of medicines. In 2006 its sales amounted to 101.8 Polish zloty, 38.18 mln dollars.

Soparma corrently pridices 210 products and exports to 28 foreign countries.

Last week the company received a First Class Investor certificate. The company is planning to build a new modern tablet plant.

The plant will be built in Sofia, on a plot near the company's ampullas plant on 16 Iliensko Shose Str. It is planned as a compact ensemble of buildings – a production building, a packaging building, a warehouse, an administrative building, and a laboratory. The plant will cover an area of 8,966 sq m on a land plot owned by Sopahrma. Total built-up area will be 13,502 sq m.

275 people will be employed in the new plant. The total value of the investment stands at 37.65 mln euros.

Sopharma posted a net consolidated profit in the amount of 20.013 mln leva (10.232 mln euros) in 2007 H1, versus 15.978 mln leva (8.169 mln euros) a year ago.

3,310 shares have changed hands so far today on BSE at prices between 7.84 leva and 7.94 leva.share.